Research and development
First written in FY2024-H1. 5 of 8 entries say "Advanced", first in FY2024. Latest entry: 2026-08-14.
56 other companies' latest entry also says "Advanced".
- 2026-08-14AdvancedFinancial results presentation
「Developed a health-check application that enables the recording and management of health conditions in the preventive-care field.」
The company disclosed the development of a health-check application combining facial recognition, an AI communication robot and rPPG, and its launch for sale by ジェネラス社. - FY2026-H1RestatedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥45.244 million.」
R&D activities continued, and total R&D expenses of ¥45.244 million for the first half of 2026 were disclosed. Although accelerating R&D through the Polish base was cited as a factor behind higher selling, general and administrative expenses, no new research results were described. - 2026-05-15AdvancedFinancial results presentation
「Research expenses for strengthening facial-recognition products increased」
The company disclosed higher research expenses related to strengthening its facial-recognition products. No new research results themselves were reported. - FY2025AdvancedAnnual report
「As research results for the current consolidated fiscal year, facial-recognition capabilities improved, enabling more stable operation at entertainment events involving tens of thousands of people. Authentication speed also increased significantly, and the Company successfully provided a solution using facial-recognition technology to prevent ticket resale. Improvements in liveness detection also enhanced spoofing prevention even with low-cost monocular cameras.」
The R&D policy was described in greater detail, with improvements in facial-recognition accuracy, authentication speed and liveness detection. These improvements supported event operations involving tens of thousands of people, ticket-resale prevention and spoofing prevention using low-cost monocular cameras. R&D expenses were ¥63.966 million. - 2026-03-04AdvancedGeneral Meetings of Shareholders
「We view as challenges the creation of synergies by combining the capabilities of newly added subsidiaries with the expertise we have accumulated, thereby launching new products and services, as well as advancing the use of AI to address the IT industry's shortage of talent and rising personnel costs.」
In addition to establishing a research and development base in Poland, the company made 株式会社Automagica, which specializes in generative AI, a subsidiary, and explicitly identified the use of AI and the launch of new products and services as challenges. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥13.300 million.」
R&D activities continued, and total R&D expenses of ¥13.300 million for the first half of 2025 were disclosed. No new research results or commercialization progress were described. - FY2024AdvancedAnnual report
「As research results for the current consolidated fiscal year, progress was made in incorporating facial-recognition technology into AI cameras, enabling the technology and cameras to work together. The Company began providing Work-Reco (ワーレコ), a solution that records worker attendance without requiring additional effort. Improvements in facial-recognition accuracy and liveness detection also led to the adoption of facial-recognition time-clock systems by corporate customers with more than 10,000 users.」
The R&D policy, AI research and product commercialization process were described in greater detail. The Company began providing Work-Reco, which combines facial-recognition technology with AI cameras. Facial-recognition time-clock systems were adopted by corporate customers with more than 10,000 users, and R&D expenses were ¥12.098 million. - FY2024-H1First statedAnnual report
「Total R&D expenses for the interim consolidated accounting period were ¥4.825 million.」
Total R&D expenses of ¥4.825 million for January through June 2024 were disclosed for the first time. No R&D targets or specific measures were described.